Nordic Nanovector intends to commercialise its product candidates through strategic alliances and partnerships with experienced oncology businesses and by establishing its own sales and marketing capabilities in selected markets.

Nordic Nanovector AS is a privately held company based in Oslo, Norway. The company was established in 2009. Our mission is to develop innovative radioimmunotherapeutics that target difficult to treat cancers using the company’s proprietary nanovector targeting technology.

April 27, 2013
Nordic Nanovector in the News. Jakter 80 mill til ny kreftmedisin, article in Finansavisen, 27. April 2013 (in Norwegian)

April 24, 2013
ANNUAL GENERAL MEETING IN NORDIC NANOVECTOR AS
The Board of Directors has convened the shareholders of Nordic Nanovector AS to the Annual General Meeting to be held on 25 April 2013 at 17:00 at Kjelsåsveien 168B, 0884 Oslo.

February 28, 2013
Oslo Cancer Cluster R&D Network Meeting "Radiation Therapy and Radiopharmaceuticals: from bench to bedside", Radiumhospitalet, Oslo, Norway.

April 11, 2013
Nordic Nanovector to present at Norsk Biotekforum Meeting: Møteplass kliniske studier, Næringslivets Hus, Oslo.

June 10, 2013
Nordic Nanovector to present results from preclinical studies at Society of Nuclear Medicine annual meeting, Vancouver, Canada.